Systemic Juvenile Idiopathic Arthritis
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of juvenile idiopathic arthritis in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.
The study will last about 264 weeks and may include up to 24 visits.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
- Participants must have completed a previous study of baricitinib for the treatment of JIA
- Participants must not have permanently stopped baricitinib in the prior study
- Participants must have not developed an allergy to baricitinib